View Clinical Trial (Medical Research Study)
Healthier Hearts and Brains in Treating Smoking: The HABITS Study
| City: |
|
Pittsburgh |
| State: |
|
Pennsylvania |
| Zip Code: |
|
15213 |
| Conditions: |
|
Smoking |
| Purpose: |
|
80 nicotine dependent adults ages 18-65 who desire to quit smoking will be screened and, if
eligible, enrolled and randomized to one of two four-week treatments for smoking cessation.
The treatments are standard behavioral therapy and Mindfulness Based Addiction Therapy
(MBAT), which is standard therapy plus mindfulness. Standard therapy and MBAT incorporate
elements of widely-used tools for smoking cessation including managing craving and strong
emotions, problem solving, tips on healthy eating and keeping active, and exercises based on
cognitive and behavioral therapy. MBAT uniquely incorporates mindfulness practice (a
relaxation therapy) into standard therapy. Participants complete questionnaires and undergo
an fMRI scan at baseline and at the end of therapy (after they complete the 4 weeks of
standard therapy or MBAT). During each scan, participants will complete a validated
smoking-related cue paradigm and a validated affect labeling paradigm.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Participants will be considered eligible for enrollment if they are between 18-65
years old, smoke at least ½ pack cigarettes per day, desire to quit smoking
(self-reported 75+ out of a possible 100), and have no contraindications for
varenicline medication therapy or fMRI scanning (such as body weight over 250 lbs,
intravascular metal devices including stents, or claustrophobia).
Exclusion Criteria:
- Participants will not be considered eligible for enrollment if they are not between
18-65 years old, smoke less than ½ pack cigarettes per day, do not desire to quit
smoking (self-reported -75 out of a possible 100), or have contraindications for
varenicline medication therapy or fMRI scanning (such as body weight over 250 lbs,
intravascular metal devices including stents, or claustrophobia).
|
| NCT ID: |
|
NCT00581464 |
| Primary Contact: |
|
Principal Investigator
Hilary Tindle, MD
University of Pittsburgh
Hilary Tindle, MD
Phone: 412 246 6929
Email: tindleha@upmc.edu
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Pittsburgh, Pennsylvania 15213
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|